# Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

> **NCT00923234** · PHASE1 · TERMINATED · sponsor: **Technische Universität Dresden**

## Conditions studied

- Myelodysplastic Syndromes
- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00923234
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** — (—)
- **Why stopped:** The primary objective has already been answered with the number of recruited patients.
- **Last updated:** 2013-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923234, "Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00923234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*